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Scutellaria barbata flavonoids alleviate 
memory deficits and neuronal injuries induced 
by composited Aβ in rats
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Abstract 
Background: The aim of the present study was to investigate the effects of Scutellaria barbata flavonoids (SBF) on 
memory impairment and neuronal injury induced by amyloid beta protein 25–35 in combination with aluminum 
trichloride (AlCl3) and recombinant human transforming growth factor-β1 (RHTGF-β1) (composited Aβ) in rats.
Methods: The composited Aβ-treated model of Alzheimer’s disease (AD)-like memory impairment and neuronal 
injury was established in male rats by right intracerebroventricular injection of composited Aβ, and the effects of SBF 
were assessed using this rat model. Spatial learning and memory of rats were assessed in the Morris water maze, and 
neuronal injury was assessed by light and electron microscopy with hematoxylin-eosin or uranyl acetate and lead 
nitrate-sodium citrate staining, respectively.
Results: In the Morris water maze, memory impairment was observed in 94.7% of the composited Aβ-treated rats. 
The composited Aβ-treated rats took longer than sham-operated rats to find the hidden platform during position 
navigation and reversal learning trials. They also spent less time swimming in the target quadrant in the probe trial. 
Optical and electron microscopic observations showed significant neuropathological changes including neuron loss 
or pyknosis in hippocampus, typical colliquative necrosis in cerebral cortex, mitochondrial swelling and cristae frag-
mentation and a large number of lipofuscin deposits in the cytoplasm. Treatment with SBF (35–140 mg/kg) reduced 
the memory impairment and neuronal injury induced by composited Aβ.
Conclusion: SBF-mediated improvement of composited Aβ-induced memory impairment and neuronal injury in 
rats provides an appropriate rationale for evaluating SBF as a promising agent for treatment of AD.
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Background
Alzheimer’s disease (AD) is a chronic and progressive 
neurodegenerative disease in the elderly, and it is accom-
panied by gradual memory loss. In general, atrophy of 
the nervous system, loss of neurons and synapses, as well 
as disorders of subcellular structure and function are 
closely associated with the occurrence and development 
of AD [1, 2]. In particular, extracellular senile plaques 
(SP), which are primarily composed of aggregated beta-
amyloid (Aβ), and intracellular neurofibrillary tangles 
(NFT), which are composed of insoluble aggregates of 
hyperphosphorylated tau protein in the brain, are con-
sidered the most important histopathogenic traits in 
AD. Multiple neurotoxic events in the brain, such as Aβ 
aggregation, tau protein hyperphosphorylation, disrup-
tion of calcium homeostasis, and production of reactive 
oxygen species, have been shown to occur when animals 
were intraventricularly injected with Aβ [3]. The depos-
ited Aβ may result in massive SP and NFT formation, 
and the combined effects of deposited Aβ and hyper-
phosphorylated tau protein exacerbate neurotoxicity 
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established using Aβ25–35 in combination with alu-
minum trichloride (AlCl3) and recombinant human 
transforming growth factor-β1 (RHTGF-β1) injected 
into the lateral cerebral ventricle (composited Aβ-treated 
rat). This model provides a comprehensive simulation of 
human histopathogenic traits [5]. Aluminum can pre-
vent conversion of sedimentary Aβ into soluble Aβ, and 
RHTGF-β1 can enhance sedimentary Aβ formation and 
accelerate occurrence of AD [6]. Thus, several compos-
ited Aβ-induced neuronal dysfunctions are relevant to 
AD, and an intervention that can decrease composited 
Aβ-mediated neuronal injury may be useful in the treat-
ment of AD.
Scutellaria barbata flavonoids (SBF), which are isolated 
from the aerial parts of S. barbata D. Don, have been 
shown to alleviate fever, inflammation, peroxidation, as 
well as improve memory deficits and neuroendocrine 
and abnormal free radical changes in ovariectomized 
rats [7–9]. However, the effects of SBF on impaired 
learning and memory and neuronal damage induced 
by composited Aβ in rats has not been reported. In the 
present study, the effects of SBF were assessed using a 
composited Aβ-treated rat model of AD-like memory 
impairment and brain injury, which was established by 
intracerebroventricular injection of Aβ25–35 in combi-
nation with AlCl3 and RHTGF-β1.
Materials
Animals
Four-month-old male Sprague–Dawley rats were pur-
chased from the Experimental Animal Center of Hebei 
Medical University (Clean grade, Certification No. scxk 
(Ji) 2010-1-003). Rats were housed in groups of four or 
five per cage with free access to food and water under 
controlled laboratory conditions with a 12-h light–dark 
cycle and an ambient temperature of 22–24  °C. Before 
the operation, the rats were allowed to acclimatize to 
the laboratory environment for 1  week. All animal pro-
cedures were carried out in accordance with the Regula-
tions of Experimental Animal Administration issued by 
the State Committee of Science and Technology of China 
on Oct. 31, 1988 [10]. All efforts were made to minimize 
the animal number and their discomfort.
Drug and reagents
SBF was prepared by the Phytochemistry Laboratory, 
Institute of Traditional Chinese Medicine, Chengde 
Medical College, Chengde City, China. One kg of dried 
aerial parts of S. barbata D. Don was boiled twice for 1 h 
with 80% alcohol, and the extract was filtered with fil-
ter paper. The filtration was performed, and the extract 
was evaporated under reduced pressure until no alcohol 
remained. The concentrated solution was adjusted to pH 
2 by adding 1 N HCl and was maintained at room tem-
perature for 24 h until the sediment completely formed. 
The sediment was SBF, and the flavonoid was not less 
than 85%. Scutellarein was the major ingredient as shown 
by high performance liquid chromatography assay [11]. 
Aβ25-35, AlCl3 and RHTGF-β1 were purchased from 
Shanghai Qiangyao Bioabiotechnology Co., Ltd (Shang-
hai, China), Tianjin Beichen Reagent Company Inc (Tian-
jin, China) and Prospect Biosystems (Newark, NJ, USA), 
respectively. Other reagents were AR grade and were 
supplied by commercial sources.
Methods
Surgical procedure
One hundred male Sprague–Dawley rats (300–350  g, 
4  months of age) were used in the experiments. Eighty 
rats were microinjected with composited Aβ into the 
right lateral cerebral ventricle and designated as com-
posited Aβ-treated rats. Twenty rats were subjected 
to a sham operation. The rats were anaesthetized with 
10% chloral hydrate (300  mg/kg, intraperitoneal) and 
restrained in a brain stereotaxic apparatus (RWD, Shen-
zhen, China). On the first day of the operation, as shown 
in Additional files 1 and 2, 1 μL of RHTGF-β1 (10 ng) was 
microinjected into the lateral cerebral ventricle area [pos-
terior (P): 1.0 mm to the bregma, lateral (L): 1.4 mm to 
the midline, and ventral (V): 4.6 mm to the skull]. A cath-
eter was inserted into the lateral cerebral ventricle area 
[posterior (P): 1.2 mm to the bregma, lateral (L): 2.0 mm 
to the midline, and ventral (V): 4.6 mm to the skull] [12]. 
On the second day of operation, 4 μg (1 μL) Aβ25–35 and 
3 μL AlCl3 (1%) were microinjected daily for 14 days in 
the morning and 5 days in the afternoon, respectively. 
The sham-operated group was subjected to the same 
operation and received a saline microinjection. Seventy-
six composited Aβ-treated rats survived, the success rate 
of the operation was 95%. Eighteen sham-operated rats 
survived, the success rate of the operation was 90%.
Experimental design
The entire experiment took 86 days and Fig.  1 showed 
the timeline of experimental design. All rats were allowed 
to recover for 45 days after the operation. The Morris 
water maze was used to screen rats for learning deficits 
and to assess their spatial memory. The rats underwent 
4 consecutive days of water maze training with 2 tri-
als per day. Composited Aβ-treated rats that displayed a 
learning deficit on day 4 of training in the Morris Water 
Maze were randomly divided into 4 groups: composited 
Aβ-treated group or 3 drug-treated groups (3 doses). 
Rats in the drug-treated groups were administered 35, 
70 and 140  mg/kg (oral) of SBF daily for 38 days. The 
sham-operated rats were given saline. The rats’ spatial 
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memory was tested in the Morris water maze over 7 con-
secutive days, from day 31 to day 37 of SBF administra-
tion (namely, day 79 to day 85 after the operation). The 
medication lasted throughout the Morris water maze test 
period. All the rats were killed by decapitation 60  min 
after the last administration of SBF or saline on day 38 of 
administration.
Screening for successful model rats and assessment 
of behavior in the Morris Water Maze
The Morris water maze was used to assess learning and 
memory and screen for successful model rats [13]. The 
Morris water maze was a stainless steel circular pool 
with a diameter of 120 cm and a depth of 50 cm. It was 
purchased from the Institute of Materia Medica, Chi-
nese Academy of Medical Science and Peking Union 
Medical College (Beijing, China). When the water maze 
test was performed, the pool water was blackened with 
several drops of ink. The water depth was 31.5 cm, and 
the temperature was maintained at 23 ± 1 °C. A circular 
transparent plexiglass platform was set 1.5 cm below the 
water surface. Each spatial signal around the maze was 
invariable during all water maze tests. For descriptive 
data collection, the pool was subdivided into four equal 
quadrants formed by imaginary lines. The hidden plat-
form was placed in the first quadrant (Q1). All swimming 
behaviors (measured by latency or trajectory) of rats were 
captured by a video camera linked to computer-based 
graphics analytic software (Institute of Materia Medica, 
Chinese Academy of Medical Science and Peking Union 
Medical College).
Screening for successful memory impairment 
of composited Aβ‑treated rats
On day 45 after the operation, all rats underwent four 
consecutive days of Morris water maze training to 
screen for memory impairment (screening for successful 
composited Aβ-treated rats) (Fig. 1). The screening ratio 
(SR) was calculated from the average latency to find the 
hidden platform on day 4 of water maze training for each 
composited Aβ-treated rat and sham-operated rats. The 
average latency to find the hidden platform on day 4 of 
water maze training for each composited Aβ-treated rat 
was “A”, and the average latency of sham-operated rats 
was “B”. Then, SR = (A − B)/B. When SR was larger than 
0.2 for a composited Aβ-treated rat, it was considered 
a successful composited Aβ-treated rat with impaired 
memory [14].
Determination of spatial memory
Spatial memory was assessed for seven consecutive days 
with two trials per day using the Morris water maze. The 
time spent finding the hidden platform was recorded, 
and an average value was calculated from the data of 
two trials to determine intraday memory performance. 
The water maze test procedure was designed such that 
the rats were allowed to swim and search for the hidden 
platform within 60 s. If a rat missed the hidden platform 
within 60 s, the experimenter then placed the rat on the 
platform. When a rat reached the hidden platform (inde-
pendently or assisted), the rat was allowed to remain 
there for 20  s, and then the rat was removed from the 
pool. Each rat was allowed a 10 s recovery time between 
the two trials. Memory measurement was divided into 
four parts: 2 days of positioning navigation trial, 1 day of 
probe trial, 3 days of reversal trial, and finally 1 day of vis-
ible platform trial [15].
Positioning navigation trial
The positioning navigation trial was used to evaluate 
memory acquisition on days 1 and 2 in the Morris water 
maze. This was performed on days 31 and 32 after initia-
tion of treatment with SBF, which corresponded to days 
79 and 80 after the operation (Fig. 1). The location of the 
Fig. 1 The timeline of experimental design
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hidden platform was the same as during screening of the 
composited Aβ-treated rats (Q1). The average value of 
latency over 2 trials was taken as the intraday memory 
acquisition score.
Probe trial
The probe trial was used to evaluate memory retention 
on day 3 of the Morris water maze test, which was con-
ducted on day 33 after initiation of treatment with SBF 
and day 81 after the operation (Fig. 1). The platform was 
removed from the pool, and the rats were allowed to 
swim 60 s and search for the target quadrant (Q1) where 
the platform was located during the positioning naviga-
tion trial. Swimming time in the target quadrant (Q1) 
was recorded for 60 s and taken as the memory retention 
score.
Reversal trial
The reversal trial was used to evaluate re-learning for 
three consecutive days on days 4, 5, and 6 of the Mor-
ris water maze test, which corresponded to day 34, 35 
and 36 of SBF treatment and day 82, 83 and 84 after the 
operation (Fig. 1). The platform was placed on the oppo-
site side of the target quadrant (Q3). The average latency 
over two trials was taken as the rats’ intraday re-learning 
achievement.
Visible platform trial
The visible platform trial was used to evaluate swimming 
speed on day 7 of the Morris water maze test. The aim 
was to exclude the influence of motivational or sensori-
motor factors upon learning and memory performance. 
All rats were subjected to a 1 day visible platform trial 
on day 37 after initiation of SBF treatment, which corre-
sponded to day 85 after the operation (Fig. 1). The plat-
form was elevated 2  cm above the water surface. The 
swimming speed of all rats in the pool was recorded.
Detection of neuronal injury
Under ether anesthesia, the rats were killed by decapita-
tion 60 min after the last administration of SBF or saline 
on day 38 of treatment (Fig. 1). For three rats from each 
group, the right hemisphere was gently separated on ice 
and then routinely processed as previously described 
[16]. Coronal sections, approximately 4  µm-thick, were 
cut and stained with hematoxylin-eosin (HE). Stained 
neurons were visualized and photographed at a magnifi-
cation of 4× or 400× using an Olympus VANOX micro-
scope from Olympus Optical Co. Ltd. (Tokyo, Japan). An 
investigator blinded to the experimental design counted 
neurons per 0.125  mm in the CA1 region of the hip-
pocampus and per 0.0352 mm2 of the cerebral cortex at 
400×. Three subfields of the hippocampal CA1 region 
and cerebral cortex were selected from each rat brain. 
The average number of normal neurons was determined 
in each group at a magnification of 400×. Neurons were 
identified as normal if they appeared undamaged with 
round or oval cell bodies, which distinguished them from 
glial cells. In addition, hippocampi of the left hemisphere 
were double-fixed with 2.5% glutaraldehyde and 1% 
osmic acid and then sectioned with an ultramicrotome. 
The sections were placed on a 200-mesh copper grid and 
stained with uranyl acetate and lead nitrate-sodium cit-
rate as described previously [17]. The ultrastructure of 
cells was observed with a JEOL 100CX II transmission 
electron microscope and photographed at a magnifica-
tion of 10,000–35,000×.
Statistical analysis
Data are presented as mean ±  SEM. Statistical analysis 
was performed using a SAS/STAT Microsoft package 
obtained from SAS, USA. Two-way analysis of variance 
(ANOVA) with repeated measures was used to analyze 
group differences in latency to reach the platform in the 
Morris water maze test, and one-way ANOVA followed 
by Duncan’s multiple-range test was used to analyze 
group differences in the probe trial and the number of 
neurons. Differences with P values <0.05 were considered 
statistically significant.
Results
Screening AD model rats using the Morris water maze test
In recording adaptive swimming, we found that the 
sham-operated rats always swam freely, and the compos-
ited Aβ-treated rats always swam around the pool perim-
eter (Fig. 2a). Over the 4 days of testing model rats in the 
Morris water maze, the time to find the hidden platform 
(latency) progressively declined in all animals. When 
the screening ratio (SR), which was based on the latency 
to find the hidden platform on day 4 for composited 
Aβ-treated and sham-operated rats, was more than 0.2, 
this animal was considered as a successful model rat. The 
percentage of successful model rats was 94.7% (Fig. 2b).
Effect of SBF on rat memory acquisition in the Morris water 
maze test
The positioning navigation trial was used to evaluate rat 
memory acquisition on day 1 and 2 of the Morris water 
maze test. During the 2  days memory acquisition trial, 
the latency to find the hidden platform progressively 
declined in all rats. However, as shown in Fig.  3, the 
latency of the composited Aβ-treated group was 540% 
and 454% [F (1, 6) = 187.37, P < 0.01] greater than that 
of the sham-operated group on days 1 and 2, respectively. 
The prolonged latency of the composited Aβ-treated 
group was significantly shortened by treatment with SBF 
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at doses of 35 mg/kg [F (1, 6) = 5.71, P < 0.05], 70 mg/
kg [F (1, 6)  =  17.51, P  <  0.01], and 140  mg/kg [F (1, 
6) = 79.67, P < 0.01].
Effect of SBF on rat memory retention in the Morris water 
maze test
The probe trial was used to evaluate rat memory reten-
tion on day 3 of the Morris water maze test. As shown in 
Fig.  4a and b, the time that composited Aβ-treated rats 
swam in the target quadrant (Q1) decreased by 32.14% 
within 60  s compared with sham control rats [F (1, 
6) = 7.16, P < 0.05]. The reduced swimming time of the 
composited Aβ-treated group was differently attenuated 
by 3 doses of SBF, which increased swimming time 4.63% 
in response to 35 mg/kg SBF, 8.40% in response to 70 mg/
kg SBF, and 25.26% in response to 140 mg/kg SBF [F (1, 
6) = 3.82, P < 0.05].
Effect of SBF on rat memory re‑learning in the Morris water 
maze test
The reversal trial was used to evaluate rat memory re-
learning on days 4, 5, and 6 of the Morris water maze test. 
Figure 3 shows that the composited Aβ-treated rats took 
113, 521, and 652% longer to find the hidden platform 
than the sham control rats [F (1, 6) =  26.55, P  <  0.01]. 
It is interesting that on days 4, 5, and 6 of the Morris 
water maze test, the 3 doses of SBF differentially short-
ened the longer latencies, which decreased 20.43, 31.24, 
and 55.53% in response to 35 mg/kg SBF [F (1, 6) = 7.23, 
P < 0.05], 51.77, 50.11, and 61.08% in response to 70 mg/
kg SBF [F (1, 6) = 17.51, P < 0.01], and 74.04, 61.5, and 
80.51% in response to 140 mg/kg SBF [F (1, 6) = 79.67, 
P < 0.01].
Effect of SBF on rat swimming speed in the Morris water 
maze test
The visible platform trial was used to evaluate rat swim-
ming speed on day 7 of training in the Morris water 
maze test. The times spent finding the visible platform 
for rats in each group were not significantly different [F 
(4, 30) = 0.79, P > 0.05]. Therefore, individual differences 
in rat swimming speed could be excluded, which indi-
cated that motivation and motor skills were essentially 
intact.
Effect of SBF on rat neuronal injuries induced 
by composited Aβ‑treatment
Three rats from each group were decapitated 60  min 
after the last administration of SBF or saline on day 38 
of drug treatment. In several composited Aβ-treated rats, 
visual inspection revealed a yellow surface, and a thin 
or collapsed cerebral cortex. Optical microscopy of HE 
stained brains from the composited Aβ-treated group 
showed marked pathological changes in neurons of the 
hippocampus and cerebral cortex, such as neurofibril-
lary degeneration, neuronophagia, nuclear pyknosis, and 
nuclear margination (Fig.  5aB1, B2), as compared with 
the sham-operated group (Fig.  5aA1, A2, A3). In addi-
tion, neurons in part of the cerebral cortex of compos-
ited Aβ-treated rats showed typical colliquative necrosis, 
which was characterized by disrupted cell membranes, 
fragmented nuclei, and extensive infiltration of inflam-
matory cells in the necrotic region (Fig. 5aB3). However, 
in composited Aβ-treated rats that had been treated 
with SBF for 38 d, neuronal injuries in the hippocampus 
Fig. 2 Screening for memory impairment of rats using the Morris 
water maze. a The adaptive swimming trajectory of rats in the 
Morris water maze. A1–A2 Sham-operated rats; B1–B2 composited 
Aβ-treated rats. b Mean latency to find the hidden platform for 4 
consecutive days of screening trials in the Morris water maze for 
sham-operated and composited Aβ-treated rats
Page 6 of 10Wu et al. Behav Brain Funct  (2016) 12:33 
and cerebral cortex were markedly attenuated in a dose-
dependent manner (Fig. 5aC1–E1, C2–E2, C3–E3).
In addition to pathological changes, the number 
of neurons was significantly reduced in the brains of 
composited Aβ-treated rats, as compared with those 
of the sham-operated group. The neuron count was 
63.86  ±  4.35% (P  <  0.01) lower than that of the sham-
operated group in 0.125  mm sections of the hippocam-
pal CA1 area and 55.46  ±  5.48% (P  <  0.01) lower in 
0.0352  mm2 sections of the cerebral cortex (Fig.  6a). It 
is noteworthy that the decreased neuron count in com-
posited Aβ-treated rats was dramatically reversed by 
treatment with SBF for 38 days. The number of neurons 
was increased 18.98% by 35 mg/kg (P < 0.05), 47.36% by 
70 mg/kg (P < 0.01), and by 140 mg/kg 106.81% (P < 0.01) 
in the hippocampus CA1 subfield and 14.24% by 35 mg/
kg (P < 0.05), 59.33% by 70 mg/kg (P < 0.01), and 85.63% 
by 140  mg/kg (P  <  0.01) in the cerebral cortex subfield 
(Fig. 6a).
The ultrastructure of neurons was examined with elec-
tron microscopy. Compared with the sham-operated 
group (Fig. 6cA), neurons in the composited Aβ-treated 
group were severely damaged, showing mitochondrial 
swelling and cristae fragmentation, increased mitochon-
drial electron density, dilation of the rough endoplasmic 
reticulum, depolymerization of polyribosomes and pol-
ymicrotubules, smaller postsynaptic density (PSD), pro-
duction of secondary lysosomes, and a large number of 
lipofuscin deposits in the cytoplasm. The nuclear mem-
brane appeared rough and sunken, euchromatin was con-
densed and denatured, myelin sheath layers were loose or 
attenuated, and internal axons and fibers were degener-
ated (Fig.  6cB). However, 140  mg/kg SBF administered 
for 38 days dramatically attenuated these neuronal path-
ological changes induced by composited Aβ, and damage 
to neuronal subcellular structure was reduced (Fig. 6bC).
Discussion
It is well known that the loss of learning and memory is 
the major clinical symptom in AD patients [18]. In the 
present study, the Morris water maze was used to assess 
memory impairment in the AD-like model rat. We found 
that the percentage of successful model rats was 94.70%, 
which indicated that the established method for screen-
ing model rats injected with Aβ25–35 in combination 
with AlCl3 and RHTGF-β1 was credible. These successful 
model rats were used to measure the effects of SBF. On 
day 1 and 2 of the positioning navigation trial, the rats in 
the composited Aβ-treated group took longer to find the 
hidden platform than the sham-operated group, which 
demonstrated impaired spatial memory acquisition in the 
composited Aβ-treated rats. On day 3 of the probe trial, 
the rats in the composited Aβ-treated group spent less 
time swimming in the target quadrant, which indicated 
decreased memory retention in composited Aβ-treated 
rats. On day 4, 5, and 6 of the memory re-learning trial, 
the rats in the composited Aβ-treated group required 
more time to find the hidden platform compared with 
rats in the sham-operated group. This result suggests 
that the composited Aβ can impair memory re-learning. 
However, when the composited Aβ-treated rats were 
treated with 35, 70 or 140 mg/kg SBF for 37 d, compos-
ited Aβ-induced impairment of memory acquisition, 
memory retention, and re-learning was reversed, which 
suggests that SBF has potential value for treatment of AD.
In the present study, light and electron microscopic 
observation showed that the rats microinjected with 
composited Aβ displayed dramatic neuropathological 
changes, including loss of neurons, nuclear pyknosis, 
neurofibrillary degeneration, neuronophagia, a signifi-
cant infiltration of inflammatory cells, and disrupted sub-
cellular structures. However, when rats injected with 
composited Aβ were treated with SBF for 38 d, the neu-
ropathological changes were ameliorated. These results 
support our previous studies [8, 9, 19–21] and suggest 
that the effect of SBF on memory deficits induced by 
composited Aβ may be derived primarily from improving 
neuron survival.
Fig. 3 Effects of SBF on memory acquisition and re-learning impair-
ment induced by composited Aβ in rats. The positioning navigation 
trial was used to evaluate memory acquisition by 2 consecutive days 
swimming achievement on day 1 and 2 in the Morris water maze test. 
These were performed on day 31 and 32 after initiation of treatment 
with SBF, which corresponded to day 79 and 80 after the operation. 
The reversal trial was used to evaluate memory re-learning of rats by 
3 consecutive days swimming score on day 4, 5, and 6 in the Morris 
water maze test, which corresponded to day 34, 35 and 36 of SBF 
treatment, namely on day 82, 83 and 84 after the operation. The line 
graph plots showed the mean latency to find the hidden platform 
for each group on day 1, 2, 4, 5, and 6 in the Morris water maze test. 
Data were analyzed by two-way ANOVA (day × group) with repeated 
measures. Mean ± SEM. n = 6. ##P < 0.01, vs. sham-operated group. 
**P < 0.01, vs. composited Aβ-treated group
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Conclusion
In summary, the current findings show that SBF can 
improve composited Aβ-induced memory deficits and 
neurodegeneration, which suggests that SBF may be par-
ticularly useful in the treatment of neurodegenerative 
diseases such as AD.
Fig. 4 Effects of SBF on memory retention impairment induced by composited Aβ in rats. The probe trial was used to evaluate memory retention 
of rats by 1 day swimming achievement on day 3 in the Morris water maze test, which was conducted on day 33 initiation of SBF treated, namely 
on day 81 after the operation. a Time spent swimming in the target quadrant within 60 s in the probe trial (no platform). Data were analyzed by 
one-way ANOVA with the multiple-range test. Mean ± SEM. n = 6. ##P < 0.01, vs. sham-operated group. *P < 0.05 vs. composited Aβ-treated group. 
b Typical swimming-tracking paths of rats in probe trial. A Sham-operated group, B Composited Aβ-treated group, C SBF 35 mg/kg group, D SBF 
70 mg/kg group, E SBF 140 mg/kg group
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Aβ-treated. b Subcellular structure of hippocampal neurons assessed by electron microscopic observation. A Sham-operated group ×12,000, scale 
bar 4 µm; B Composited Aβ-treated group; showing mitochondrial swelling, cristae fragmentation, and increased electron density (▲), rough 
endoplasmic reticulum dilation (*), polyribosome and polymicrotubule depolymerization, secondary lysosome (↑) production, a large number of 
lipofuscin (→) deposits in the cytoplasm, rough and curved nuclear membranes, condensed and denatured euchromatin (★), loose or attenu-
ated myelin sheath layers, internal axon and fiber degeneration, and almost normal golgiosomes. ×10,000, scale bar 5 µm; C SBF 140 mg/kg group, 
×12,000, scale bar 4 µm
(See figure on previous page.) 
Fig. 5 Effects of SBF on pathological changes in the hippocampus and cerebral cortex induced by composited Aβ in rats. Representative images 
of hippocampal and cerebral cortical neurons stained with HE. A1–E1 Hippocampus ×40; A2–E2 Hippocampus CA1 ×400; A3–E3 Cerebral cortex 
×400. A1–A3 Sham-operated group; B1–B3 Composited Aβ-treated group; showing loss of neurons, neurofibrillary degeneration (→), neuronopha-
gia (←), nuclear pyknosis (↗), nuclear margination (↙), colliquative necrosis (★)with disrupted cellular membranes. Nuclei were fragmented, and 
large numbers of inflammatory cells infiltrated regions of the cerebral cortex in composited Aβ-treated rats. C1–C3 SBF 35 mg/kg group; D1–D3 SBF 
70 mg/kg group; E1–E3 SBF 140 mg/kg group. Scale bar 10 or 100 µm
Additional files
Additional file 1. The site of RHTGF-β1 by right intracerebroventricular 
injection.
Additional file 2. The site of Aβ 25-35 and AlCl3 by right intracer-
ebroventricular injection.
Page 10 of 10Wu et al. Behav Brain Funct  (2016) 12:33 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Acknowledgements
Authors thank to Yang Gao, Shuai Ma and Xiaojing Wang for technical 
supported.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Data scope and type Database
Morris water maze Institute of Materia Medica, Chinese
Academy of Medical Science and 
Peking
Union Medical College (Beijing, 
China)
Graphics analytic software Institute of Materia Medica, Chinese
Academy of Medical Science and 
Peking
Union Medical College (Beijing, 
China)




Rats were provided by the Medical Experimental Animal Administrative Com-
mittee of Hebei Province (China) and all experiments were in accordance with 
the Regulations of Experimental Animal Administration issued by the State 
Committee of Science and Technology of China on Oct. 31, 1988.
Funding
The project was supported by Hebei Provincial Natural Science Foundation 
(No. C2009001007, H2014406048) and Hebei Provincial Administration of 
Traditional Chinese Medicine (Nos. 05027, 2014062) of China.
Received: 11 June 2016   Accepted: 28 November 2016
References
 1. Ruan Z, Zhang HY. Advances in studies of drugs treatment of Alzheimer’s 
disease. Chin New Drugs Clin Rem. 2012;31:175–87.
 2. Ma YX, Yu ZW. Contemporary Dementia Medicine. 2007, 1st ed, Beijing: 
Science and Technology Literature Press; pp 597–520.
 3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 
2007;8:101–12.
 4. Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 
2010;77:32–42.
 5. Fang F, Yan Y, Feng ZH, Liu XQ, Wen M, Huang H. Study of Alzheimer’s dis-
ease model induced multiple factors. Chongqing Med. 2007;36:146–51.
 6. Guo K, Wu XG, Miao H, Cheng JJ, Cui YD, Shang YZ. Regulation and 
mechanism of Scutellaria barbata flavonoids on apoptosis of cortical 
neurons and cytochondriome induced by composited Aβ. Chin Hosp 
Pharm J. 2015;35:1994–9.
 7. Dong YC, Shang YZ. Advances of Scutellaria Barbata in pharmacology. J 
Chengde Med Coll. 2009;26:98–100.
 8. Xi YL, Liu MH, Zhang XF, Li M, Dong YC, Miao H, Shang YZ. Improvement 
of Scutellaria Barbata flavonoid on impaired memory of ovariectomy rats. 
Chin J Gerontol. 2011;31:242–5.
 9. Xi YL, Zhang SF, Miao H, Shang YZ. Changes of MDA level, GSH-Px activity 
and NO content in ovariectomized rats and the interventional effect 
exerted by flavonoids from Scutellaria Barbata. Chin J Hosp Pharma J. 
2011;31:1996–8.
 10. The Ministry of Science and Technology of the People’s Republic of China. 
Regulations for the administration of affairs concerning experimental 
animals. 1988-10-31.
 11. Xi YL, Miao H, Shang YZ. Measurement of Scutellaria Barbata flavonoid 
concentration with ultraviolet spectrophotometry. J Chengde Med Col. 
2009;26:66–7.
 12. Paxinos G, Watson C, Carrive P, Kirkcaldie M, Ashwell Ken WS. Chemo-
architectonic atlas of the rat forebrain. Chemoarchitectonic atlas of the 
rat brain. 2008, 2nd ed. New York: Academic Press; pp 275–80.
 13. Morris R. Developments of a water-maze procedure for studying spatial 
learning in the rats. J Neurosic Methods. 1984;11:47–60.
 14. Zhao XL, Fang XB, Li DP. Establishing vascular dementia model in rats. J 
Chin Med Univ. 2002;31(166–7):176.
 15. Yu JC, Liu CZ, Zhang XZ, Han JX. Acupuncture improved cognitive 
impairment caused by multi-infarct dementia in rats. Physiol Behav. 
2005;86:434–41.
 16. Shang YZ, Miao H, Cheng JJ, Qi JM. Effects of amelioration of total 
flavonoids from stems and leaves of Scutellaria baicalensis Georgi on 
cognitive deficits, neuronal damage and free radicals disorder induced by 
cerebral ischemia in rats. Biol Pharm Bull. 2006;29:805–10.
 17. Song HR, Cheng JJ, Miao HJ, Shang YZ. Scutellaria flavonoid supple-
mentation reverses ageing-related cognitive impairment and neuronal 
changes in aged rats. Brain Inj. 2009;23:146–53.
 18. Ubhi K, Masliah E. Alzheimer’s disease: recent advances and future per-
spectives. J Alzheimers Dis. 2013;33(S1):85–94.
 19. Yin XX, Zhang SF, Xi YL, Miao H, Shang YZ. Effect of flavonoids from Scutel-
laria barbata on protein expression of apoptotic genes in the brain of 
ovariectomized rats. Chin J New Drugs. 2010;19:1255–9.
 20. Fan Y, Wu XG, Zhao HX, Shang YZ. Effects of Scutellaria barbata flavonoids 
on abnormal expression of NOS, HSP70 and apoE induced by Aβ25-35in 
rat astrocytes. Chin J Pathophysiol. 2014;30(359–63):379.
 21. Zhao HX, Guo K, Cui YD, Wu XG, Shang YZ. Effect of Scutellaria barbata 
flavonoids on abnormal changes of Bcl-2, Bax, Bcl-xL and Bak protein 
expression in mitochondrial membrane induced by composite Aβ25-35. 
Chin J Pathophysiol. 2014;30:2262–6.
